Disposable Intranasal Atomization Device, 0.5mL Prefilled Nasal Spray Assembly, Blister Box Packaging, 1 Piece/Blister Case, 200 Blister Case/Inner Box, 5 Inner Boxes/Case, 1000 Pieces/Case

Nest Scientific Disposable Intranasal Atomization Device, 0.5mL Prefilled Nasal Spray Assembly,  Blister Box Packaging, 1 Piece/Blister Case, 200 Blister Case/Inner Box, 5 Inner Boxes/Case, 1000 Pieces/Case (201302)

Key Features

• 0.5 mL Prefilled nasal spray assembly
• 1 piece per blister case, 200 blister cases per inner box and 5 inner boxes per case. 1000 pieces per case
• For intransal delivery of vaccines and other medications

• Nasal vaccination induces both mucosal (protection at site of infection) and systemic immunity

• Painless and hygenic way to deliver medications without needles

• Droplets 10-70 μm in diameter
• FDA Registered, Type III DMF 40629

Product Details

Stable & Durable Material

• Made from borosilicate glass, the same material trusted for pharmaceutical packaging of biological agents and vaccines. This glass ensures strong chemical durability and excellent shock resistance.

Hermetically Sealed for Protection

• Each device is secured with a protection cap that contains an embedded sealing ring. This design ensures the device is leak-proof and virus-resistant during handling, transfer, and transportation.

Superior Atomization

• An atomization cavity with a precision turbine design guarantees a perfect atomization effect. This produces uniformly atomized particles that are evenly distributed on the human mucous membrane for optimal therapeutic delivery. 

Precise & Uniform Dosing

• The integrated Precise Dose Limiter ensures the uniformity of every single dose, providing reliable and consistent medication administration.

Single-Use, Self-Destruct Design

• Designed exclusively for single use, the device features a self-destruct mechanism. After administration, the stopper permanently sticks in the syringe, preventing it from being taken out or used a second time, which helps ensure sterility and safety

Intranasal medication, delivered via absorption through the nasal mucosa, represents an effective treatment approach. The nasal mucosa's moist, smooth surface and abundant blood vessels make it an optimal pathway for drug administration. This method, often facilitated by specialized devices, enables targeted delivery to alleviate inflammation, control bleeding, combat bacterial infections, and ease nasal congestion. Once absorbed into the bloodstream, the medication circulates systemically throughout the body. 

Compared to intravenous injection or other routes, intranasal delivery offers distinct benefits. First, the lower activity of hydrolases in the nasal mucosa minimizes degradation of sensitive compounds like polypeptides, hormones, and vaccines, preserving their therapeutic efficacy—unlike the harsher gastrointestinal environment. Second, it circumvents the liver's "first-pass effect," reducing the risk of hepatic toxicity associated with oral medications. Third, it provides high bioavailability and facilitates direct targeting to the brain via olfactory pathways. Finally, its simplicity enhances patient compliance, particularly for infants and children, with fewer adverse effects overall.

In recent years, nasal spray vaccines have emerged as a promising frontier in research and clinical application, leveraging these unique intranasal advantages. Studies demonstrate that nasal mucosal immunization elicits both localized and systemic immune responses, often matching or surpassing the potency of intravenous vaccines and outperforming oral ones in intensity and effectiveness. This innovation expands the scope of intranasal administration, opening new avenues for preventive medicine.